BLIS Technologies Company Description

BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity.

The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance.

It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.

BLIS Technologies Limited

Country	New Zealand
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	39
CEO	Scott Johnson

Contact Details

Address: 442 Moray Place Dunedin, 9016 New Zealand
Phone	64 3 474 0988
Website	blis.co.nz

Stock Details

Ticker Symbol	BLT
Exchange	New Zealand Stock Exchange
Fiscal Year	April - March
Reporting Currency	NZD
ISIN Number	NZBLTE0002S8
SIC Code	2834

Key Executives

Name	Position
Scott Johnson	Chief Executive Officer
Richard Wingham	Chief Financial Officer